Halozyme Therapeutics Bids to Acquire German Competitor Evotec
By Sabela Ojea
Halozyme Therapeutics submitted a bid to acquire German drug developer Evotec in a deal with an equity value of 2 billion euros ($2.11 billion.)
The San Diego-based biopharmaceutical company on Thursday said it is proposing to acquire competitor Evotec for EUR11 per share, representing a 109% premium to its share price on Oct. 15, the day prior to a report on Triton Partners' stake in Evotec.
Halozyme Chief Executive Helen Torley said the acquisition would create a U.S., European innovative services company that would accelerate the discovery and development of a diverse pipeline of treatments.
The company added that the takeover wouldn't be subject to any financing contingency, as it has significant cash reserves on-hand and a strong balance sheet.
Halozyme's M&A disclosure came shortly after Bloomberg reported earlier this week that Triton Partners was considering a takeover bid for Evotec, citing people familiar with the matter.
Write to Sabela Ojea at sabela.ojea@wsj.com; @sabelaojeaguix
(END) Dow Jones Newswires
November 14, 2024 17:20 ET (22:20 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Most Discussed
No relevant data is available